OspA chimeras and use thereof in vaccines

摘要

The invention relates to the development of chimeric OspA molecules for use in against Lyme disease or borreliosis vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies.